-
FDA approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible gram-positive organisms including Staphylococcus aureus (MRSA and MSSA), Streptococcus agalactiae, Streptococcus anginosus group, Streptococcus pyogenes, and Enterococcus faecalis.
-
147 patients on stable antiretroviral therapy (ART) were randomized to receiving rosuvustatin 10 mg daily or placebo. After 24 weeks rosovustatin both reduced cystatin C and slowed kidney function decline as assessed by a serum creatinine-based equation.
-
Asymptomatic carriage of C. difficile in adult hospitalized patients varies regionally, but estimates suggest that 4% to 23% of patients being admitted to hospital in the U.S. may be colonized with toxogenic strains of C. difficile (TCD).
-
-
Ventilator-associated pneumonia (VAP) is a serious complication for intubated patients. It causes significant morbidity and mortality, increases healthcare costs and is the main reason for antibiotic use in the intensive care unit (ICU).
-
-
New data and consensus discussions provide updated guidance about the use of hepatitis A vaccine for young children, in US residents, and in individuals who are traveling very soon after their pretravel consultations.
-
An excellent update on rabies was provided by Charles E. Rupprecht, the Rabies Section Chief of the CDC, during the Symposium, Control of Zoonoses: A Veterinary Perspective at the recent 51st annual ASTMH meeting in Denver, Colo.
-
FDA Approves Generic Version of AstraZenecas Prilosec; Pegasys
Approved To Treat Hepatitis C; HRT Reduces Alzheimers Risk, Study
Says; Heparin Plus Alteplase More Effective; Digoxin Effects Differ By
Sex; McClellan Named FDA Commissioner; FDA Actions
-
The emergence of chronic wasting disease, a transmissible spongiform encephalopathy in North American cervids, raises concern about potential transmission to humans, as has occurred elsewhere with bovine spongiform encephalopathy and vCJD.